Form 4: Modular Medical Executive Paul DiPerna Acquires Options Contingent on FDA Clearance

Paul DiPerna, a director, 10% owner, and officer of Modular Medical, Inc., acquired options to purchase 58,560 shares of common stock, contingent on FDA clearance by December 31, 2024.

Summary

• Paul DiPerna, a director, 10% owner, and officer of Modular Medical, Inc., filed a Form 4.
• The form reports the acquisition of an option to purchase 58,560 shares of Modular Medical's common stock at an exercise price of $1.71 on August 22, 2024.
• The options vest only if Modular Medical receives FDA 510(K) clearance for its initial pump product by December 31, 2024.
• If the FDA clearance is not received by this date, the options will not vest and will terminate on January 1, 2025.
• The options expire on August 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of options by an insider suggests confidence, but the contingency on FDA clearance introduces uncertainty.

Positives

• The acquisition of options by a key insider could signal confidence in the company's prospects and the likelihood of FDA clearance.

Negatives

• The options are contingent on FDA clearance, introducing uncertainty regarding their potential value.

Risks

• Failure to obtain FDA 510(K) clearance by December 31, 2024, will result in the options not vesting and terminating.

Future Outlook

The vesting of the options is contingent on the company receiving FDA 510(K) clearance for its initial pump product by December 31, 2024, which will be a key milestone for the company.

Industry Context

The medical device industry is heavily regulated, and FDA clearance is a critical step for bringing new products to market. The success of Modular Medical's initial pump product is crucial for its future growth.

Comparison to Industry Standards

• Obtaining FDA 510(k) clearance is a common milestone for medical device companies, similar to companies like Insulet (PODD) and Tandem Diabetes Care (TNDM) who have successfully navigated the regulatory process for their insulin pump products.
• The timeline for FDA clearance can vary, but a successful submission and approval are essential for commercialization.

Stakeholder Impact

• Shareholders: The potential for FDA clearance and subsequent product launch could positively impact the company's stock price.
• Employees: Successful FDA clearance could lead to increased job security and growth opportunities.
• Customers: The availability of a new pump product could provide additional treatment options.

Next Steps

• Modular Medical needs to obtain FDA 510(K) clearance for its initial pump product by December 31, 2024, for the options to vest.
• Monitor the progress of the FDA submission and any related announcements.

Key Dates